BetterLife PharmaBETRF -2.06%29 3-Year ROIIC % is 1,315.90 as of Jan. 2026, which is 10007% above its 10-year median of 13.02. GuruFocus rates BETRF with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,320 Biotechnology companies, BetterLife Pharma ranks better than 95.08% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
BetterLife Pharma's 3-Year ROIIC % for the quarter that ended in Jan. 2026 was 1,315.90%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for BetterLife Pharma's 3-Year ROIIC % or its related term are showing as below:
BETRF's 3-Year ROIIC % is ranked better than 95.08% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs BETRF: 1315.90
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
BetterLife Pharma 3-Year ROIIC % Related Terms
BetterLife Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for BetterLife Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BETRF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, BetterLife Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BetterLife Pharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BetterLife Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where BetterLife Pharma's 3-Year ROIIC % falls into.
BetterLife Pharma's 3-Year ROIIC % for the quarter that ended in Jan. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -1.314 (Jan. 2026) - -6.897 (Jan. 2023) )
/
( 0.953 (Jan. 2026) - 0.557 (Jan. 2023) )
=
5.583
/
0.396
=
1,409.85%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
BetterLife Pharma (BETRF) has a 3-Year ROIIC % of 1,315.90 as of Jan. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on BetterLife Pharma and its competitors. This is 10007% above median its historical median of 13.02. According to the industry distribution chart, BetterLife Pharma ranks #65 out of 1320 companies in the Biotechnology industry, placing it in the top 4.9%.
Is BetterLife Pharma's 3-Year ROIIC % too high?
BetterLife Pharma's current 3-Year ROIIC % of 1,315.90 is 10007% above median its 10-year median of 13.02. Based on the distribution chart, BetterLife Pharma ranks #65 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BetterLife Pharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does BetterLife Pharma's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BetterLife Pharma ranks #65 out of 1320 companies for 3-Year ROIIC %. This places BetterLife Pharma in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on BetterLife Pharma and its competitors. BetterLife Pharma's current 3-Year ROIIC % is 1,315.90, which is 10007% above median its own 10-year median of 13.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BetterLife Pharma stock overvalued right now?
BetterLife Pharma (BETRF) has a current 3-Year ROIIC % of 1,315.90. The current 3-Year ROIIC % is 1,315.90, which is 10007% above median its 10-year median of 13.02. BetterLife Pharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For BetterLife Pharma (BETRF), the current 3-Year ROIIC % is 1,315.90 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BetterLife Pharma Inc is a biopharmaceutical company engaged in the development of patented pharmaceuticals. It is an emerging biotechnology company mainly focused on developing compounds for the treatment of mental disorders. It is also refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight viral infections. The Company operates in one industry segment, development and commercialization of patented pharmaceuticals within one geographical area.
29GF Score
Get the complete analysis for BETRF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BETRF has been successfully added to your 
